More Positives for PCSK9 inhibitors and the LDL-C Hypothesis

The co-investigator for the ODYSSEY study of alirocumab discusses which patients will benefit most from the expensive biologic and why the mortality reduction finding comes with qualifiers.

Source: Medscape Cardiology Podcast - March 14, 2018 Category: Cardiology Authors: Medscape Source Type: podcasts